Q1 Earnings Forecast for VERA Issued By Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Vera Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.95) for the quarter. Wedbush has a "Neutral" rating and a $26.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.02) EPS and Q4 2026 earnings at ($0.83) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the business earned ($0.56) earnings per share.

VERA has been the subject of several other research reports. Guggenheim upped their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. Finally, Cantor Fitzgerald lowered their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $63.33.

Vera Therapeutics Stock Down 3.8%

VERA traded down $0.86 on Thursday, hitting $21.63. 208,479 shares of the company were exchanged, compared to its average volume of 776,090. The firm has a 50-day moving average price of $24.07 and a two-hundred day moving average price of $34.52. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -8.29 and a beta of 1.28.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its position in Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after purchasing an additional 1,300,410 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after buying an additional 437,940 shares during the period. FMR LLC boosted its holdings in Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after buying an additional 267,842 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after acquiring an additional 369,387 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in shares of Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after acquiring an additional 340,488 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.